
 NATIONAL CANCER INSTITUTE  BBRB Biorepositories and Biospecimen Research Branch		Biospecimen Pre-Analytical Variables (BPV) Ovary Local Pathology Review Form	
PR-0009-F2	VER. 03.02	Effective Date: 07/16/2014	Page 1 of 6

BPV Case

ID: _____

Affix BPV Case ID Label

Form Completed By: _____

Date on Which Form Was Completed:

____/____/____
 (MM/DD/YYYY)

Tissue Bank ID: _____

Ovarian Slide Pathology Review

1. Slide ID examined by pathologist:

2. Parent specimen ID of the sample from which this slide was derived:

3. Organ of origin:
 Select one:
 - ☐ Ovary
 - ☐ Peritoneum
 - ☐ Fallopian tube
 - ☐ Indeterminate
 - ☐ Other (specify)

If Other was selected, record other organ of origin:

PR-0009-F2
VER. 03.02
Effective Date: 07/16/2014

Page 2 of 6

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

 Date Completed: ____/____/____
 (MM/DD/YYYY)

4. Histologic type:

Select one:

- ☐ Brenner Tumor, malignant type (WHO code: 9000/3)
- ☐ Carcinosarcoma (Malignant mullerian mixed tumor) (WHO code: 8950/3)
- ☐ Clear cell borderline tumor (WHO code: 8310/1)
- ☐ Clear cell carcinoma (WHO code: 8310/3)
- ☐ Endometrioid borderline tumor (WHO code: 8380/1)
- ☐ Endometrioid carcinoma (WHO code: 8380/3)
- ☐ Granulosa cell tumor (WHO code 8620/1)
- ☐ Malignant germ cell tumor (WHO code: 9064/3)
- Specify types and %:**
- ☐ Mixed epithelial borderline tumor (WHO code: 8323/1)
- Specify types and %:**
- ☐ Mixed epithelial carcinoma (WHO code: 8323/3)
- Specify types and %:**
- ☐ Mucinous borderline tumor, endocervical (seromuninous) type (WHO code: 8472/1)
- ☐ Mucinous borderline tumor, intestinal type (WHO code: 3472/1)
- ☐ Mucinous carcinoma (WHO code: 8480/3)
- ☐ Mucinous cystadenocarcinoma (WHO code: 8470/3)
- ☐ Serous borderline tumor (WHO code: 8441/1)
- ☐ Serous carcinoma (WHO code: 8441/3)
- ☐ Serous cystadenocarcinoma (WHO code: 8441/3)
- ☐ Squamous cell carcinoma
- ☐ Transitional cell borderline carcinoma (WHO code: 8120/1)
- ☐ Transitional cell carcinoma (WHO code: 8120/3)
- ☐ Undifferentiated carcinoma (WHO code: 8020/3)
- ☐ Other sex cord-stromal tumor (WHO code: 8590/1)
- Specify types and %:**
- ☐ Other
- Specify other histologic type or histologic type details:**

Specify histologic type details where applicable:

PR-0009-F2
VER. 03.02
Effective Date: 07/16/2014

Page 3 of 6

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

 Date Completed: ____/____/____
 (MM/DD/YYYY)

5. **Greatest tumor dimension on slide:** _____ (mm)
6. **Percent of cross-sectional surface area of entire slide composed of tumor focus (includes necrotic tumor):** _____ %
7. **Percent of tumor nuclei by cell count of the entire slide (number of tumor epithelial cell nuclei as compared to all cell nuclei):** _____ %
8. **Percent of cross-sectional surface area of entire slide composed of necrotic tissue:**
 _____ %

Note: BPV case acceptance criteria require necrosis percentage of <20% of the entire slide AND tumor content of ≥50% tumor nuclei.

Histologic Profile Quantitative Assessment of Tumor Should Total 100%.

9. **Histologic profile quantitative assessment:**
 Percent viable tumor by surface area (not including stroma): _____ %
 Percent necrotic tumor by surface area: _____ %
 Percent tumor stroma by surface area: _____ %
 Percent non-cellular component by surface area: _____ %
 (i.e., mucin, hemorrhage, blood clot, etc.)
If present, describe non-cellular component:

 Histologic profile total % (should equal 100%): _____ %

10. What histologic grading system was applied?

Select One:

- ☐ WHO grading system

Record WHO histologic grade:

- ☐ G1: Well differentiated
☐ G2: Moderately differentiated
☐ G3: Poorly differentiated
☐ G4: Undifferentiated
☐ GX: Cannot be assessed

OR

- ☐ Two-tier grading system

Record two-tier histologic grade:

- ☐ Low grade
☐ High grade

PR-0009-F2

VER. 03.02

Effective Date: 07/16/2014

Page 4 of 6

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: ____/____/____
(MM/DD/YYYY)

Tumor Staging per AJCC 7th Edition

11. pT: Pathologic spread primary tumor (AJCC 7th edition):

Select one:

- ☐ pTX
- ☐ pT0
- ☐ pT1
 - ☐ pT1a
 - ☐ pT1b
 - ☐ pT1c
- ☐ pT2
 - ☐ pT2a
 - ☐ pT2b
 - ☐ pT2c
- ☐ pT3
 - ☐ pT3a
 - ☐ pT3b
 - ☐ pT3c

12. pN: Pathologic spread lymph nodes (AJCC 7th edition):

Select one:

- ☐ pNX
- ☐ pN0
- ☐ pN1

13. M: Distant metastases (AJCC 7th edition):

Select one:

- ☐ cM0
- ☐ cM1
- ☐ pM1

PR-0009-F2
VER. 03.02
Effective Date: 07/16/2014

Page 5 of 6

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

 Date Completed: ____/____/_____
 (MM/DD/YYYY)

14. Pathologic tumor stage grouping (FIGO):

Select One:

- ☐ Stage 1
- ☐ Stage 1A
- ☐ Stage 1B
- ☐ Stage 1C
- ☐ Stage 2
- ☐ Stage 2A
- ☐ Stage 2B
- ☐ Stage 2C
- ☐ Stage 3
- ☐ Stage 3A
- ☐ Stage 3B
- ☐ Stage 3C
- ☐ Stage 4
- ☐ Stage unknown

15. Did pathology review of the hematoxylin and eosin slide derived from quality control formalin-fixed paraffin-embedded tumor tissue confirm the histological type to be eligible for BPV study?

Select One:

- ☐ Yes
- ☐ No

16. This slide meets the microscopic analysis criteria of the BPV project of necrosis percentage of <20% AND tumor content of ≥50% tumor nuclei:

Select One:

- ☐ Yes
- ☐ No

If No is selected, specify what findings do not meet the microscopic analysis criteria of the BPV project:

17. Pathology review comments:

PR-0009-F2

VER. 03.02

Effective Date: 07/16/2014

Page 6 of 6

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: ____/____/____
(MM/DD/YYYY)

Concordance With Diagnostic Pathology Report

18. This slide is consistent with the findings of the diagnostic pathology report for this case:

Select One:

- ☐ Yes
☐ No

If No is selected, specify what findings are not consistent with the diagnostic pathology report:

19. Name of local biospecimen source site reviewing pathologist:

20. Date of slide review by the pathologist:

21. Data entry in local pathology review form was performed by: